➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Express Scripts

Last Updated: April 14, 2021

DrugPatentWatch Database Preview


➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Doxycycline patents expire, and when can generic versions of Doxycycline launch?

Doxycycline is a drug marketed by Alembic Pharms Ltd, Cosette, Impax Labs Inc, Lupin Ltd, Mayne Pharma Inc, Mylan Pharms Inc, Par Pharm, Sandoz Inc, Sun Pharm Inds Ltd, Watson Labs, Zydus Pharms, Chartwell Life Sci, Mylan Labs Ltd, West-ward Pharms Int, Heritage Pharms Inc, Lannett Co Inc, Mylan, Sun Pharm Industries, Pliva, Medicis, Actavis Labs Fl Inc, Ajanta Pharma Ltd, Amneal Pharms, Changzhou Pharm, Halsey, Heather, Hikma Intl Pharms, Interpharm, Mutual Pharm, Nostrum Labs Inc, Pvt Form, Ranbaxy, Superpharm, Warner Chilcott, Zhejiang Yongtai, Actavis Elizabeth, Prinston Inc, Acella, Amneal Pharms Co, Apotex, Cadila, Caribe Holdings, Emcure Pharms Ltd, Epic Pharma Llc, Heritage Pharma, Larken Labs, Novel Labs Inc, and Vintage Pharms. and is included in ninety-four NDAs.

The generic ingredient in DOXYCYCLINE is doxycycline hyclate. There are twenty-eight drug master file entries for this compound. Seventy-five suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Doxycycline

A generic version of DOXYCYCLINE was approved as doxycycline hyclate by CARIBE HOLDINGS on November 8th, 1982.

  Start Trial

Drug patent expirations by year for DOXYCYCLINE
Drug Prices for DOXYCYCLINE

See drug prices for DOXYCYCLINE

Drug Sales Revenue Trends for DOXYCYCLINE

See drug sales revenues for DOXYCYCLINE

Recent Clinical Trials for DOXYCYCLINE

Identify potential brand extensions & 505(b)(2) entrants

University of PennsylvaniaPhase 4
Zhuzhou Qianjin Pharmaceutical Co., Ltd., 801, Zhuzhou Avenue, Tianyuan District, Zhuzhou, ChinaPhase 1/Phase 2
University of KarachiPhase 1/Phase 2

See all DOXYCYCLINE clinical trials

Pharmacology for DOXYCYCLINE
Medical Subject Heading (MeSH) Categories for DOXYCYCLINE
Paragraph IV (Patent) Challenges for DOXYCYCLINE
Tradename Dosage Ingredient NDA Submissiondate
ORACEA CAPSULE;ORAL doxycycline 050805 2008-12-12
ORACEA CAPSULE;ORAL doxycycline 050805 2008-12-11

US Patents and Regulatory Information for DOXYCYCLINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ajanta Pharma Ltd DOXYCYCLINE HYCLATE doxycycline hyclate CAPSULE;ORAL 211012-001 Sep 24, 2018 DISCN No No   Start Trial   Start Trial   Start Trial
Sun Pharm Industries DOXYCYCLINE HYCLATE doxycycline hyclate CAPSULE;ORAL 062676-002 Jul 10, 1986 AB RX No No   Start Trial   Start Trial   Start Trial
Lannett Co Inc DOXYCYCLINE doxycycline TABLET;ORAL 065285-001 Dec 8, 2005 AB RX No No   Start Trial   Start Trial   Start Trial
West-ward Pharms Int DOXYCYCLINE doxycycline hyclate INJECTABLE;INJECTION 062569-001 Mar 9, 1988 AP RX No Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.